Joint sale of medicine

Huh Eun-chul, left, president of Green Cross Corp., poses with Kim Na-kyung, country head of Baxalta Korea, a biopharmaceutical company, after signing a sales contract for Rixubis, a hemophilia B medicine, at his firm’s headquarters in Yongin, Gyeonggi Province, May 19. Under the accord, Green Cross will have the exclusive right to distribute and sell Baxalta’s Rixubis until 2019. / Courtesy of Green Cross